BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen YM, Liu Y, Zhou RF, Chen XL, Wang C, Tan XY, Wang LJ, Zheng RD, Zhang HW, Ling WH, Zhu HL. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci Rep. 2016;6:19076. [PMID: 26743949 DOI: 10.1038/srep19076] [Cited by in Crossref: 122] [Cited by in F6Publishing: 124] [Article Influence: 20.3] [Reference Citation Analysis]
Number Citing Articles
1 Golonka R, Yeoh BS, Vijay-Kumar M. Dietary Additives and Supplements Revisited: The Fewer, the Safer for Liver and Gut Health. Curr Pharmacol Rep 2019;5:303-16. [PMID: 32864300 DOI: 10.1007/s40495-019-00187-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
2 Ho KM, Kalgudi S, Corbett JM, Litton E. Gut microbiota in surgical and critically ill patients. Anaesth Intensive Care 2020;48:179-95. [PMID: 32131606 DOI: 10.1177/0310057X20903732] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Robinson EJ, Taddeo MC, Chu X, Shi W, Wood C, Still C, Rovnyak VG, Rovnyak D. Aqueous Metabolite Trends for the Progression of Nonalcoholic Fatty Liver Disease in Female Bariatric Surgery Patients by Targeted 1H-NMR Metabolomics. Metabolites 2021;11:737. [PMID: 34822395 DOI: 10.3390/metabo11110737] [Reference Citation Analysis]
4 Lyu M, Wang YF, Fan GW, Wang XY, Xu SY, Zhu Y. Balancing Herbal Medicine and Functional Food for Prevention and Treatment of Cardiometabolic Diseases through Modulating Gut Microbiota. Front Microbiol 2017;8:2146. [PMID: 29167659 DOI: 10.3389/fmicb.2017.02146] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 13.4] [Reference Citation Analysis]
5 Chen S, Jiang PP, Yu D, Liao GC, Wu SL, Fang AP, Chen PY, Wang XY, Luo Y, Long JA, Zhong RH, Liu ZY, Li CL, Zhang DM, Zhu HL. Effects of probiotic supplementation on serum trimethylamine-N-oxide level and gut microbiota composition in young males: a double-blinded randomized controlled trial. Eur J Nutr 2021;60:747-58. [PMID: 32440731 DOI: 10.1007/s00394-020-02278-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
6 Portincasa P, Bonfrate L, Khalil M, Angelis MD, Calabrese FM, D’amato M, Wang DQ, Di Ciaula A. Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Biomedicines 2022;10:83. [DOI: 10.3390/biomedicines10010083] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
7 Gruppen EG, Garcia E, Connelly MA, Jeyarajah EJ, Otvos JD, Bakker SJL, Dullaart RPF. TMAO is Associated with Mortality: Impact of Modestly Impaired Renal Function. Sci Rep 2017;7:13781. [PMID: 29061990 DOI: 10.1038/s41598-017-13739-9] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 10.8] [Reference Citation Analysis]
8 Khan A, Ding Z, Ishaq M, Bacha AS, Khan I, Hanif A, Li W, Guo X. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates. Int J Biol Sci 2021;17:818-33. [PMID: 33767591 DOI: 10.7150/ijbs.56214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 Niska-Blakie J, Gopinathan L, Low KN, Kien YL, Goh CMF, Caldez MJ, Pfeiffenberger E, Jones OS, Ong CB, Kurochkin IV, Coppola V, Tessarollo L, Choi H, Kanagasundaram Y, Eisenhaber F, Maurer-Stroh S, Kaldis P. Knockout of the non-essential gene SUGCT creates diet-linked, age-related microbiome disbalance with a diabetes-like metabolic syndrome phenotype. Cell Mol Life Sci 2020;77:3423-39. [PMID: 31722069 DOI: 10.1007/s00018-019-03359-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
10 Caussy C, Tripathi A, Humphrey G, Bassirian S, Singh S, Faulkner C, Bettencourt R, Rizo E, Richards L, Xu ZZ, Downes MR, Evans RM, Brenner DA, Sirlin CB, Knight R, Loomba R. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nat Commun 2019;10:1406. [PMID: 30926798 DOI: 10.1038/s41467-019-09455-9] [Cited by in Crossref: 84] [Cited by in F6Publishing: 84] [Article Influence: 28.0] [Reference Citation Analysis]
11 Jayakumar S, Loomba R. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Aliment Pharmacol Ther 2019;50:144-58. [PMID: 31149745 DOI: 10.1111/apt.15314] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
12 Han H, Jiang Y, Wang M, Melaku M, Liu L, Zhao Y, Everaert N, Yi B, Zhang H. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis. Crit Rev Food Sci Nutr 2021;:1-18. [PMID: 34404276 DOI: 10.1080/10408398.2021.1966738] [Reference Citation Analysis]
13 Kwong EK, Puri P. Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease. Transl Gastroenterol Hepatol 2021;6:3. [PMID: 33409398 DOI: 10.21037/tgh.2020.02.18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
14 Heianza Y, Zhou T, He H, DiDonato JA, Bray GA, Sacks FM, Qi L. Changes in gut-microbiota-related metabolites and long-term improvements in lipoprotein subspecies in overweight and obese adults: the POUNDS lost trial. Int J Obes (Lond) 2021. [PMID: 34426648 DOI: 10.1038/s41366-021-00939-7] [Reference Citation Analysis]
15 Giuffrè M, Campigotto M, Campisciano G, Comar M, Crocè LS. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature. Am J Physiol Gastrointest Liver Physiol 2020;318:G889-906. [PMID: 32146836 DOI: 10.1152/ajpgi.00161.2019] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 23.0] [Reference Citation Analysis]
16 Mansour A, Hekmatdoost A, Mirmiran P. What are the main areas of focus to prevent or treat non‐alcoholic fatty liver disease? J Dig Dis 2019;20:271-7. [DOI: 10.1111/1751-2980.12751] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
17 Park E, Jeong JJ, Won SM, Sharma SP, Gebru YA, Ganesan R, Gupta H, Suk KT, Kim DJ. Gut Microbiota-Related Cellular and Molecular Mechanisms in the Progression of Nonalcoholic Fatty Liver Disease. Cells 2021;10:2634. [PMID: 34685614 DOI: 10.3390/cells10102634] [Reference Citation Analysis]
18 Fei N, Bruneau A, Zhang X, Wang R, Wang J, Rabot S, Gérard P, Zhao L. Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease. mBio 2020;11:e03263-19. [PMID: 32019793 DOI: 10.1128/mBio.03263-19] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
19 Hrncir T, Hrncirova L, Kverka M, Hromadka R, Machova V, Trckova E, Kostovcikova K, Kralickova P, Krejsek J, Tlaskalova-Hogenova H. Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions. Microorganisms 2021;9:957. [PMID: 33946843 DOI: 10.3390/microorganisms9050957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
20 Orabi D, Berger NA, Brown JM. Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. Cancers (Basel) 2021;13:3473. [PMID: 34298687 DOI: 10.3390/cancers13143473] [Reference Citation Analysis]
21 Wang SZ, Yu YJ, Adeli K. Role of Gut Microbiota in Neuroendocrine Regulation of Carbohydrate and Lipid Metabolism via the Microbiota-Gut-Brain-Liver Axis. Microorganisms. 2020;8. [PMID: 32272588 DOI: 10.3390/microorganisms8040527] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
22 Akhmedov VA, Gaus OV. Role of intestinal microbiota in the formation of non-alcoholic fatty liver disease. Terapevticheskii arkhiv 2019;91:143-8. [DOI: 10.26442/00403660.2019.02.000051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
23 Guo F, Han M, Lin S, Ye H, Chen J, Zhu H, Lin W. Enteromorpha prolifera polysaccharide prevents high- fat diet-induced obesity in hamsters: A NMR-based metabolomic evaluation. J Food Sci 2021;86:3672-85. [PMID: 34191277 DOI: 10.1111/1750-3841.15818] [Reference Citation Analysis]
24 Stewart AM, Stewart KL, Yeates TO, Bobik TA. Advances in the World of Bacterial Microcompartments. Trends Biochem Sci 2021;46:406-16. [PMID: 33446424 DOI: 10.1016/j.tibs.2020.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
25 Zhang C, Ma S, Wu J, Luo L, Qiao S, Li R, Xu W, Wang N, Zhao B, Wang X, Zhang Y, Wang X. A specific gut microbiota and metabolomic profiles shifts related to antidiabetic action: The similar and complementary antidiabetic properties of type 3 resistant starch from Canna edulis and metformin. Pharmacol Res 2020;159:104985. [PMID: 32504839 DOI: 10.1016/j.phrs.2020.104985] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
26 Alves FM, Caldow MK, Trieu J, Naim T, Montgomery MK, Watt MJ, Lynch GS, Koopman R. Choline administration attenuates aspects of the dystrophic pathology in mdx mice. Clinical Nutrition Experimental 2019;24:83-91. [DOI: 10.1016/j.yclnex.2018.12.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
27 Moran-Ramos S, López-Contreras BE, Canizales-Quinteros S. Gut Microbiota in Obesity and Metabolic Abnormalities: A Matter of Composition or Functionality? Arch Med Res 2017;48:735-53. [PMID: 29292011 DOI: 10.1016/j.arcmed.2017.11.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
28 Stewart KL, Stewart AM, Bobik TA. Prokaryotic Organelles: Bacterial Microcompartments in E. coli and Salmonella. EcoSal Plus 2020;9. [PMID: 33030141 DOI: 10.1128/ecosalplus.ESP-0025-2019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
29 Manor O, Zubair N, Conomos MP, Xu X, Rohwer JE, Krafft CE, Lovejoy JC, Magis AT. A Multi-omic Association Study of Trimethylamine N-Oxide. Cell Rep 2018;24:935-46. [PMID: 30044989 DOI: 10.1016/j.celrep.2018.06.096] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 29.0] [Reference Citation Analysis]
30 Castillo-Castro C, Martagón-Rosado AJ, Ortiz-Lopez R, Garrido-Treviño LF, Villegas-Albo M, Bosques-Padilla FJ. Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome. World J Hepatol 2021; 13(11): 1494-1511 [PMID: 34904026 DOI: 10.4254/wjh.v13.i11.1494] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Du J, Shen L, Tan Z, Zhang P, Zhao X, Xu Y, Gan M, Yang Q, Ma J, Jiang A, Tang G, Jiang Y, Jin L, Li M, Bai L, Li X, Wang J, Zhang S, Zhu L. Betaine Supplementation Enhances Lipid Metabolism and Improves Insulin Resistance in Mice Fed a High-Fat Diet. Nutrients 2018;10:E131. [PMID: 29373534 DOI: 10.3390/nu10020131] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 9.8] [Reference Citation Analysis]
32 Jichitu A, Bungau S, Stanescu AMA, Vesa CM, Toma MM, Bustea C, Iurciuc S, Rus M, Bacalbasa N, Diaconu CC. Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. Diagnostics (Basel) 2021;11:689. [PMID: 33921359 DOI: 10.3390/diagnostics11040689] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Schwenger KJ, Clermont-Dejean N, Allard JP. The role of the gut microbiome in chronic liver disease: the clinical evidence revised. JHEP Rep 2019;1:214-26. [PMID: 32039372 DOI: 10.1016/j.jhepr.2019.04.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 14.7] [Reference Citation Analysis]
34 Guasch-Ferré M, Hu FB, Ruiz-Canela M, Bulló M, Toledo E, Wang DD, Corella D, Gómez-Gracia E, Fiol M, Estruch R, Lapetra J, Fitó M, Arós F, Serra-Majem L, Ros E, Dennis C, Liang L, Clish CB, Martínez-González MA, Salas-Salvadó J. Plasma Metabolites From Choline Pathway and Risk of Cardiovascular Disease in the PREDIMED (Prevention With Mediterranean Diet) Study. J Am Heart Assoc 2017;6:e006524. [PMID: 29080862 DOI: 10.1161/JAHA.117.006524] [Cited by in Crossref: 51] [Cited by in F6Publishing: 31] [Article Influence: 10.2] [Reference Citation Analysis]
35 Chen W, Zhang X, Xu M, Jiang L, Zhou M, Liu W, Chen Z, Wang Y, Zou Q, Wang L. Betaine prevented high-fat diet-induced NAFLD by regulating the FGF10/AMPK signaling pathway in ApoE-/- mice. Eur J Nutr 2021;60:1655-68. [PMID: 32808060 DOI: 10.1007/s00394-020-02362-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Castaño-Rodríguez N, Mitchell HM, Kaakoush NO. NAFLD, Helicobacter species and the intestinal microbiome. Best Pract Res Clin Gastroenterol 2017;31:657-68. [PMID: 29566909 DOI: 10.1016/j.bpg.2017.09.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
37 León-Mimila P, Villamil-Ramírez H, Li XS, Shih DM, Hui ST, Ocampo-Medina E, López-Contreras B, Morán-Ramos S, Olivares-Arevalo M, Grandini-Rosales P, Macías-Kauffer L, González-González I, Hernández-Pando R, Gómez-Pérez F, Campos-Pérez F, Aguilar-Salinas C, Larrieta-Carrasco E, Villarreal-Molina T, Wang Z, Lusis AJ, Hazen SL, Huertas-Vazquez A, Canizales-Quinteros S. Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes. Diabetes Metab 2021;47:101183. [PMID: 32791310 DOI: 10.1016/j.diabet.2020.07.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
38 Tilg H, Adolph TE, Moschen AR. Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. Hepatology 2021;73:833-42. [PMID: 32780879 DOI: 10.1002/hep.31518] [Cited by in Crossref: 74] [Cited by in F6Publishing: 62] [Article Influence: 74.0] [Reference Citation Analysis]
39 Perumpail BJ, Li AA, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A. The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD. Diseases 2019;7:E27. [PMID: 30823570 DOI: 10.3390/diseases7010027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
40 Moran-Ramos S, He X, Chin EL, Tovar AR, Torres N, Slupsky CM, Raybould HE. Nopal feeding reduces adiposity, intestinal inflammation and shifts the cecal microbiota and metabolism in high-fat fed rats. PLoS One 2017;12:e0171672. [PMID: 28196086 DOI: 10.1371/journal.pone.0171672] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
41 Gao X, Tian Y, Randell E, Zhou H, Sun G. Unfavorable Associations Between Serum Trimethylamine N-Oxide and L-Carnitine Levels With Components of Metabolic Syndrome in the Newfoundland Population. Front Endocrinol (Lausanne) 2019;10:168. [PMID: 30972022 DOI: 10.3389/fendo.2019.00168] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
42 Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res 2021;7:11. [PMID: 33490737 DOI: 10.20517/2394-5079.2020.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
43 Flores-Guerrero JL, Post A, van Dijk PR, Connelly MA, Garcia E, Navis G, Bakker SJL, Dullaart RPF. Circulating trimethylamine-N-oxide is associated with all-cause mortality in subjects with nonalcoholic fatty liver disease. Liver Int 2021. [PMID: 33993608 DOI: 10.1111/liv.14963] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Muzsik-kazimierska A, Szwengiel A, Nikrandt G, Chmurzynska A. Lower plasma glutathione, choline, and betaine concentrations are associated with fatty liver in postmenopausal women. Nutrition Research 2022. [DOI: 10.1016/j.nutres.2022.02.004] [Reference Citation Analysis]
45 Martín-Mateos R, Albillos A. The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease. Front Immunol 2021;12:660179. [PMID: 33936094 DOI: 10.3389/fimmu.2021.660179] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
46 Pan XF, Yang JJ, Shu XO, Moore SC, Palmer ND, Guasch-Ferré M, Herrington DM, Harada S, Eliassen H, Wang TJ, Gerszten RE, Albanes D, Tzoulaki I, Karaman I, Elliott P, Zhu H, Wagenknecht LE, Zheng W, Cai H, Cai Q, Matthews CE, Menni C, Meyer KA, Lipworth LP, Ose J, Fornage M, Ulrich CM, Yu D. Associations of circulating choline and its related metabolites with cardiometabolic biomarkers: an international pooled analysis. Am J Clin Nutr 2021;114:893-906. [PMID: 34020444 DOI: 10.1093/ajcn/nqab152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Liu C, Wang YL, Yang YY, Zhang NP, Niu C, Shen XZ, Wu J. Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases. FASEB J 2021;35:e21871. [PMID: 34473374 DOI: 10.1096/fj.202100939R] [Reference Citation Analysis]
48 Chu H, Duan Y, Yang L, Schnabl B. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut 2019;68:359-70. [PMID: 30171065 DOI: 10.1136/gutjnl-2018-316307] [Cited by in Crossref: 149] [Cited by in F6Publishing: 131] [Article Influence: 49.7] [Reference Citation Analysis]
49 Krueger ES, Lloyd TS, Tessem JS. The Accumulation and Molecular Effects of Trimethylamine N-Oxide on Metabolic Tissues: It's Not All Bad. Nutrients 2021;13:2873. [PMID: 34445033 DOI: 10.3390/nu13082873] [Reference Citation Analysis]
50 Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2018;15:425-439. [PMID: 29713021 DOI: 10.1038/s41575-018-0010-0] [Cited by in Crossref: 118] [Cited by in F6Publishing: 108] [Article Influence: 39.3] [Reference Citation Analysis]
51 Cai H, Wen Z, Zhao L, Yu D, Meng K, Yang P. Lactobacillus plantarum FRT4 alleviated obesity by modulating gut microbiota and liver metabolome in high-fat diet-induced obese mice. Food Nutr Res 2022;66. [PMID: 35721808 DOI: 10.29219/fnr.v66.7974] [Reference Citation Analysis]
52 Wang J, Wu S, Cui J, Ding Z, Meng Q, Sun H, Li B, Teng J, Dong Y, Aschner M, Wu S, Li X, Chen R. The influences of ambient fine particulate matter constituents on plasma hormones, circulating TMAO levels and blood pressure: A panel study in China. Environ Pollut 2021;:118746. [PMID: 34968616 DOI: 10.1016/j.envpol.2021.118746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Liu ZY, Tan XY, Li QJ, Liao GC, Fang AP, Zhang DM, Chen PY, Wang XY, Luo Y, Long JA, Zhong RH, Zhu HL. Trimethylamine N-oxide, a gut microbiota-dependent metabolite of choline, is positively associated with the risk of primary liver cancer: a case-control study. Nutr Metab (Lond). 2018;15:81. [PMID: 30479648 DOI: 10.1186/s12986-018-0319-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
54 Shah A, Macdonald GA, Morrison M, Holtmann G. Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework. Am J Gastroenterol 2020;115:814-22. [PMID: 32250997 DOI: 10.14309/ajg.0000000000000604] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
55 Ciavarella A, Gnocchi D, Custodero C, Lenato GM, Fiore G, Sabbà C, Mazzocca A. Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease. Thromb Res 2021;198:139-50. [PMID: 33340925 DOI: 10.1016/j.thromres.2020.12.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
56 Bekhit AEA, Giteru SG, Holman BWB, Hopkins DL. Total volatile basic nitrogen and trimethylamine in muscle foods: Potential formation pathways and effects on human health. Compr Rev Food Sci Food Saf 2021;20:3620-66. [PMID: 34056832 DOI: 10.1111/1541-4337.12764] [Reference Citation Analysis]
57 Song J, Huang M, Shi X, Li X, Chen X, He Z, Li J, Xu G, Zheng J. T329S Mutation in the FMO3 Gene Alleviates Lipid Metabolic Diseases in Chickens in the Late Laying Period. Animals (Basel) 2021;12:48. [PMID: 35011153 DOI: 10.3390/ani12010048] [Reference Citation Analysis]
58 Nilsson Å, Duan RD. Pancreatic and mucosal enzymes in choline phospholipid digestion. Am J Physiol Gastrointest Liver Physiol 2019;316:G425-45. [PMID: 30576217 DOI: 10.1152/ajpgi.00320.2018] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
59 Zhao ZH, Lai JK, Qiao L, Fan JG. Role of gut microbial metabolites in nonalcoholic fatty liver disease. J Dig Dis. 2019;20:181-188. [PMID: 30706694 DOI: 10.1111/1751-2980.12709] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
60 Wang X, Xia J, Jiang C. Role of gut microbiota in the development of non-alcoholic fatty liver disease. Liver Research 2019;3:25-30. [DOI: 10.1016/j.livres.2019.01.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Niederseer D, Wernly B, Aigner E, Stickel F, Datz C. NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. J Clin Med 2021;10:467. [PMID: 33530440 DOI: 10.3390/jcm10030467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
62 Martínez-Montoro JI, Kuchay MS, Balaguer-Román A, Martínez-Sánchez MA, Frutos MD, Fernández-García JC, Ramos-Molina B. Gut microbiota and related metabolites in the pathogenesis of nonalcoholic steatohepatitis and its resolution after bariatric surgery. Obes Rev 2021;:e13367. [PMID: 34729904 DOI: 10.1111/obr.13367] [Reference Citation Analysis]
63 Zhou D, Fan JG. Microbial metabolites in non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25(17): 2019-2028 [PMID: 31114130 DOI: 10.3748/wjg.v25.i17.2019] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 34] [Article Influence: 13.0] [Reference Citation Analysis]
64 Di Ciaula A, Baj J, Garruti G, Celano G, De Angelis M, Wang HH, Di Palo DM, Bonfrate L, Wang DQ, Portincasa P. Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. J Clin Med 2020;9:E2648. [PMID: 32823983 DOI: 10.3390/jcm9082648] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 24.5] [Reference Citation Analysis]
65 Witjes JJ, Smits LP, Pekmez CT, Prodan A, Meijnikman AS, Troelstra MA, Bouter KEC, Herrema H, Levin E, Holleboom AG, Winkelmeijer M, Beuers UH, van Lienden K, Aron-Wisnewky J, Mannisto V, Bergman JJ, Runge JH, Nederveen AJ, Dragsted LO, Konstanti P, Zoetendal EG, de Vos W, Verheij J, Groen AK, Nieuwdorp M. Donor Fecal Microbiota Transplantation Alters Gut Microbiota and Metabolites in Obese Individuals With Steatohepatitis. Hepatol Commun 2020;4:1578-90. [PMID: 33163830 DOI: 10.1002/hep4.1601] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
66 Baranova A, Maltseva D, Tonevitsky A. Adipose may actively delay progression of NAFLD by releasing tumor-suppressing, anti-fibrotic miR-122 into circulation. Obes Rev 2019;20:108-18. [PMID: 30248223 DOI: 10.1111/obr.12765] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
67 Acharya C, Bajaj JS. Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease. Gastroenterology 2021;160:556-72. [PMID: 33253686 DOI: 10.1053/j.gastro.2020.10.056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
68 Li R, Mao Z, Ye X, Zuo T. Human Gut Microbiome and Liver Diseases: From Correlation to Causation. Microorganisms 2021;9:1017. [PMID: 34066850 DOI: 10.3390/microorganisms9051017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 Grabherr F, Grander C, Effenberger M, Adolph TE, Tilg H. Gut Dysfunction and Non-alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne). 2019;10:611. [PMID: 31555219 DOI: 10.3389/fendo.2019.00611] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
70 Li X, Hong J, Wang Y, Pei M, Wang L, Gong Z. Trimethylamine-N-Oxide Pathway: A Potential Target for the Treatment of MAFLD. Front Mol Biosci 2021;8:733507. [PMID: 34660695 DOI: 10.3389/fmolb.2021.733507] [Reference Citation Analysis]
71 Barrea L, Muscogiuri G, Annunziata G, Laudisio D, de Alteriis G, Tenore GC, Colao A, Savastano S. A New Light on Vitamin D in Obesity: A Novel Association with Trimethylamine-N-Oxide (TMAO). Nutrients 2019;11:E1310. [PMID: 31185686 DOI: 10.3390/nu11061310] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
72 Marzullo P, Di Renzo L, Pugliese G, De Siena M, Barrea L, Muscogiuri G, Colao A, Savastano S; Obesity Programs of nutrition, Education, Research and Assessment (OPERA) Group. From obesity through gut microbiota to cardiovascular diseases: a dangerous journey. Int J Obes Suppl 2020;10:35-49. [PMID: 32714511 DOI: 10.1038/s41367-020-0017-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
73 Tilg H, Zmora N, Adolph TE, Elinav E. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol 2020;20:40-54. [DOI: 10.1038/s41577-019-0198-4] [Cited by in Crossref: 179] [Cited by in F6Publishing: 171] [Article Influence: 59.7] [Reference Citation Analysis]
74 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. Publisher Correction: The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 2018;15:785. [PMID: 29785003 DOI: 10.1038/s41575-018-0031-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
75 Giraud J, Saleh M. Host-Microbiota Interactions in Liver Inflammation and Cancer. Cancers (Basel) 2021;13:4342. [PMID: 34503151 DOI: 10.3390/cancers13174342] [Reference Citation Analysis]
76 Garcia E, Shalaurova I, Matyus SP, Wolak-Dinsmore J, Oskardmay DN, Connelly MA. Quantification of choline in serum and plasma using a clinical nuclear magnetic resonance analyzer. Clin Chim Acta 2022;524:106-12. [PMID: 34871562 DOI: 10.1016/j.cca.2021.11.031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Gheorghe G, Bungău S, Ceobanu G, Ilie M, Bacalbaşa N, Bratu OG, Vesa CM, Găman MA, Diaconu CC. The non-invasive assessment of hepatic fibrosis. J Formos Med Assoc 2021;120:794-803. [PMID: 32861550 DOI: 10.1016/j.jfma.2020.08.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
78 Du J, Shen L, Zhang P, Tan Z, Cheng X, Luo J, Zhao X, Yang Q, Gu H, Jiang A, Ma J, Tang Q, Jin L, Shuai S, Li M, Jiang Y, Tang G, Bai L, Li X, Wang J, Zhang S, Zhu L. The regulation of skeletal muscle fiber-type composition by betaine is associated with NFATc1/MyoD. J Mol Med (Berl) 2018;96:685-700. [PMID: 29876588 DOI: 10.1007/s00109-018-1657-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
79 Wu Y, Rong X, Pan M, Wang T, Yang H, Chen X, Xiao Z, Zhao C. Integrated Analysis Reveals the Gut Microbial Metabolite TMAO Promotes Inflammatory Hepatocellular Carcinoma by Upregulating POSTN. Front Cell Dev Biol 2022;10:840171. [DOI: 10.3389/fcell.2022.840171] [Reference Citation Analysis]
80 Hydes TJ, Ravi S, Loomba R, E Gray M. Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH. Clin Mol Hepatol 2020;26:383-400. [PMID: 32674529 DOI: 10.3350/cmh.2020.0067] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
81 Jardon KM, Canfora EE, Goossens GH, Blaak EE. Dietary macronutrients and the gut microbiome: a precision nutrition approach to improve cardiometabolic health. Gut 2022;71:1214-26. [PMID: 35135841 DOI: 10.1136/gutjnl-2020-323715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
82 Guo Y, Ding PH, Liu LJ, Shi L, Mao TY, Li JX, Wang YL. Gegen Qinlian Decoction Attenuates High-Fat Diet-Induced Steatohepatitis in Rats via Gut Microbiota. Evid Based Complement Alternat Med 2018;2018:7370891. [PMID: 30671129 DOI: 10.1155/2018/7370891] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
83 Yang XF, Lu M, You L, Gen H, Yuan L, Tian T, Li CY, Xu K, Hou J, Lei M. Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology. Chin Med 2021;16:62. [PMID: 34315516 DOI: 10.1186/s13020-021-00470-x] [Reference Citation Analysis]
84 Chen Q, Wang Y, Jiao F, Shi C, Pei M, Wang L, Gong Z. Betaine inhibits Toll-like receptor 4 responses and restores intestinal microbiota in acute liver failure mice. Sci Rep 2020;10:21850. [PMID: 33318565 DOI: 10.1038/s41598-020-78935-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
85 Yang S, Li X, Yang F, Zhao R, Pan X, Liang J, Tian L, Li X, Liu L, Xing Y, Wu M. Gut Microbiota-Dependent Marker TMAO in Promoting Cardiovascular Disease: Inflammation Mechanism, Clinical Prognostic, and Potential as a Therapeutic Target. Front Pharmacol 2019;10:1360. [PMID: 31803054 DOI: 10.3389/fphar.2019.01360] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 16.0] [Reference Citation Analysis]
86 de Faria Ghetti F, Oliveira DG, de Oliveira JM, de Castro Ferreira LEVV, Cesar DE, Moreira APB. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr. 2018;57:861-876. [PMID: 28875318 DOI: 10.1007/s00394-017-1524-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 8.6] [Reference Citation Analysis]
87 Zhao G, He F, Wu C, Li P, Li N, Deng J, Zhu G, Ren W, Peng Y. Betaine in Inflammation: Mechanistic Aspects and Applications. Front Immunol 2018;9:1070. [PMID: 29881379 DOI: 10.3389/fimmu.2018.01070] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 17.0] [Reference Citation Analysis]
88 Yu H, Geng WC, Zheng Z, Gao J, Guo DS, Wang Y. Facile Fluorescence Monitoring of Gut Microbial Metabolite Trimethylamine N-oxide via Molecular Recognition of Guanidinium-Modified Calixarene. Theranostics 2019;9:4624-32. [PMID: 31367245 DOI: 10.7150/thno.33459] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
89 Song J, Shi X, Li X, Liang Q, Zeng L, Li G, Yan Y, Xu G, Zheng J. Associations of the T329S Polymorphism in Flavin-Containing Monooxygenase 3 With Atherosclerosis and Fatty Liver Syndrome in 90-Week-Old Hens. Front Vet Sci 2022;9:868602. [DOI: 10.3389/fvets.2022.868602] [Reference Citation Analysis]
90 Aron-wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020;17:279-97. [DOI: 10.1038/s41575-020-0269-9] [Cited by in Crossref: 220] [Cited by in F6Publishing: 181] [Article Influence: 110.0] [Reference Citation Analysis]
91 Hu Y, Sun Q, Liu J, Jia Y, Cai D, Idriss AA, Omer NA, Zhao R. In ovo injection of betaine alleviates corticosterone-induced fatty liver in chickens through epigenetic modifications. Sci Rep 2017;7:40251. [PMID: 28059170 DOI: 10.1038/srep40251] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
92 Sookoian S, Puri P, Castaño GO, Scian R, Mirshahi F, Sanyal AJ, Pirola CJ. Nonalcoholic steatohepatitis is associated with a state of betaine-insufficiency. Liver Int 2017;37:611-9. [PMID: 27614103 DOI: 10.1111/liv.13249] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
93 Shao M, Ye Z, Qin Y, Wu T. Abnormal metabolic processes involved in the pathogenesis of non-alcoholic fatty liver disease (Review). Exp Ther Med 2020;20:26. [PMID: 32934691 DOI: 10.3892/etm.2020.9154] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
94 Kim M, Huda MN, O'Connor A, Albright J, Durbin-Johnson B, Bennett BJ. Hepatic transcriptional profile reveals the role of diet and genetic backgrounds on metabolic traits in female progenitor strains of the Collaborative Cross. Physiol Genomics 2021;53:173-92. [PMID: 33818129 DOI: 10.1152/physiolgenomics.00140.2020] [Reference Citation Analysis]
95 Lemoinne S, Kemgang A, Ben Belkacem K, Straube M, Jegou S, Corpechot C, Chazouillères O, Housset C, Sokol H; Saint-Antoine IBD Network. Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. Gut 2020;69:92-102. [PMID: 31003979 DOI: 10.1136/gutjnl-2018-317791] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 36.0] [Reference Citation Analysis]
96 Caussy C, Loomba R. Gut microbiome, microbial metabolites and the development of NAFLD. Nat Rev Gastroenterol Hepatol 2018;15:719-20. [PMID: 30158571 DOI: 10.1038/s41575-018-0058-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 10.7] [Reference Citation Analysis]
97 Garcia E, Osté MCJ, Bennett DW, Jeyarajah EJ, Shalaurova I, Gruppen EG, Hazen SL, Otvos JD, Bakker SJL, Dullaart RPF, Connelly MA. High Betaine, a Trimethylamine N-Oxide Related Metabolite, Is Prospectively Associated with Low Future Risk of Type 2 Diabetes Mellitus in the PREVEND Study. J Clin Med 2019;8:E1813. [PMID: 31683780 DOI: 10.3390/jcm8111813] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
98 Simon TG, Roelstraete B, Hagström H, Sundström J, Ludvigsson JF. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut 2021:gutjnl-2021-325724. [PMID: 34489307 DOI: 10.1136/gutjnl-2021-325724] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
99 Garcia E, Wolak-Dinsmore J, Wang Z, Li XS, Bennett DW, Connelly MA, Otvos JD, Hazen SL, Jeyarajah EJ. NMR quantification of trimethylamine-N-oxide in human serum and plasma in the clinical laboratory setting. Clin Biochem 2017;50:947-55. [PMID: 28624482 DOI: 10.1016/j.clinbiochem.2017.06.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
100 Massey W, Brown JM. The Gut Microbial Endocrine Organ in Type 2 Diabetes. Endocrinology 2021;162:bqaa235. [PMID: 33373432 DOI: 10.1210/endocr/bqaa235] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
101 Lai Z, Chen J, Ding C, Wong K, Chen X, Pu L, Huang Q, Chen X, Cheng Z, Liu Y, Tan X, Zhu H, Wang L. Association of Hepatic Global DNA Methylation and Serum One-Carbon Metabolites with Histological Severity in Patients with NAFLD. Obesity (Silver Spring) 2020;28:197-205. [PMID: 31785086 DOI: 10.1002/oby.22667] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
102 Smolders L, de Wit NJW, Balvers MGJ, Obeid R, Vissers MMM, Esser D. Natural Choline from Egg Yolk Phospholipids Is More Efficiently Absorbed Compared with Choline Bitartrate; Outcomes of A Randomized Trial in Healthy Adults. Nutrients 2019;11:E2758. [PMID: 31766273 DOI: 10.3390/nu11112758] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
103 Li D, Ke Y, Zhan R, Liu C, Zhao M, Zeng A, Shi X, Ji L, Cheng S, Pan B, Zheng L, Hong H. Trimethylamine-N-oxide promotes brain aging and cognitive impairment in mice. Aging Cell 2018;17:e12768. [PMID: 29749694 DOI: 10.1111/acel.12768] [Cited by in Crossref: 80] [Cited by in F6Publishing: 70] [Article Influence: 20.0] [Reference Citation Analysis]
104 Aragonès G, González-García S, Aguilar C, Richart C, Auguet T. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease. Biomed Res Int 2019;2019:8507583. [PMID: 30719448 DOI: 10.1155/2019/8507583] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
105 Hakhamaneshi MS, Abdolahi A, Vahabzadeh Z, Abdi M, Andalibi P. Toll-Like Receptor 4: A Macrophage Cell Surface Receptor Is Activated By Trimethylamine-N-Oxide. Cell J 2021;23:516-22. [PMID: 34837678 DOI: 10.22074/cellj.2021.7849] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Yang JJ, Shu XO, Herrington DM, Moore SC, Meyer KA, Ose J, Menni C, Palmer ND, Eliassen H, Harada S, Tzoulaki I, Zhu H, Albanes D, Wang TJ, Zheng W, Cai H, Ulrich CM, Guasch-Ferré M, Karaman I, Fornage M, Cai Q, Matthews CE, Wagenknecht LE, Elliott P, Gerszten RE, Yu D. Circulating trimethylamine N-oxide in association with diet and cardiometabolic biomarkers: an international pooled analysis. Am J Clin Nutr 2021;113:1145-56. [PMID: 33826706 DOI: 10.1093/ajcn/nqaa430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
107 Zhao D, Liu X, Zhao S, Li Z, Qin X. 1H NMR-Based Fecal Metabolomics Reveals Changes in Gastrointestinal Function of Aging Rats Induced by d-Galactose. Rejuvenation Res 2021;24:86-96. [PMID: 32847490 DOI: 10.1089/rej.2020.2352] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
108 Aragonès G, Colom-Pellicer M, Aguilar C, Guiu-Jurado E, Martínez S, Sabench F, Antonio Porras J, Riesco D, Del Castillo D, Richart C, Auguet T. Circulating microbiota-derived metabolites: a "liquid biopsy? Int J Obes (Lond) 2020;44:875-85. [PMID: 31388096 DOI: 10.1038/s41366-019-0430-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
109 Kriss M, Verna EC, Rosen HR, Lozupone CA. Functional Microbiomics in Liver Transplantation: Identifying Novel Targets for Improving Allograft Outcomes. Transplantation 2019;103:668-78. [PMID: 30507741 DOI: 10.1097/TP.0000000000002568] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
110 Wang F, Xu J, Jakovlić I, Wang W, Zhao Y. Dietary betaine reduces liver lipid accumulation via improvement of bile acid and trimethylamine- N -oxide metabolism in blunt-snout bream. Food Funct 2019;10:6675-89. [DOI: 10.1039/c9fo01853k] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
111 Chen YH, Wu WK, Wu MS. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review. Int J Mol Sci 2020;21:E5999. [PMID: 32825440 DOI: 10.3390/ijms21175999] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
112 Tomlinson JAP, Wheeler DC. The role of trimethylamine N-oxide as a mediator of cardiovascular complications in chronic kidney disease. Kidney Int 2017;92:809-15. [PMID: 28807612 DOI: 10.1016/j.kint.2017.03.053] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 10.0] [Reference Citation Analysis]
113 Iruzubieta P, Medina JM, Fernández-López R, Crespo J, de la Cruz F. A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression. J Clin Med 2020;9:E1369. [PMID: 32392712 DOI: 10.3390/jcm9051369] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
114 Masoodi M, Gastaldelli A, Hyötyläinen T, Arretxe E, Alonso C, Gaggini M, Brosnan J, Anstee QM, Millet O, Ortiz P, Mato JM, Dufour JF, Orešič M. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34508238 DOI: 10.1038/s41575-021-00502-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 30.0] [Reference Citation Analysis]
115 Zhang C, Bjornson E, Arif M, Tebani A, Lovric A, Benfeitas R, Ozcan M, Juszczak K, Kim W, Kim JT, Bidkhori G, Ståhlman M, Bergh PO, Adiels M, Turkez H, Taskinen MR, Bosley J, Marschall HU, Nielsen J, Uhlén M, Borén J, Mardinoglu A. The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non-alcoholic fatty liver disease. Mol Syst Biol 2020;16:e9495. [PMID: 32337855 DOI: 10.15252/msb.209495] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
116 Xie C, Halegoua-DeMarzio D. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter? Nutrients. 2019;11. [PMID: 31752378 DOI: 10.3390/nu11112837] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
117 Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020;72:558-577. [PMID: 31622696 DOI: 10.1016/j.jhep.2019.10.003] [Cited by in Crossref: 141] [Cited by in F6Publishing: 151] [Article Influence: 47.0] [Reference Citation Analysis]
118 Rajakovich LJ, Balskus EP. Metabolic functions of the human gut microbiota: the role of metalloenzymes. Nat Prod Rep 2019;36:593-625. [PMID: 30452039 DOI: 10.1039/c8np00074c] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 9.7] [Reference Citation Analysis]
119 Chen W, Xu M, Xu M, Wang Y, Zou Q, Xie S, Wang L. Effects of betaine on non-alcoholic liver disease. Nutr Res Rev 2021;:1-11. [PMID: 33818349 DOI: 10.1017/S0954422421000056] [Reference Citation Analysis]
120 Hernandez GV, Smith VA, Melnyk M, Burd MA, Sprayberry KA, Edwards MS, Peterson DG, Bennet DC, Fanter RK, Columbus DA, Steibel JP, Glanz H, Immoos C, Rice MS, Santiago-Rodriguez TM, Blank J, VanderKelen JJ, Kitts CL, Piccolo BD, La Frano MR, Burrin DG, Maj M, Manjarin R. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH. Am J Physiol Gastrointest Liver Physiol 2020;318:G582-609. [PMID: 32003601 DOI: 10.1152/ajpgi.00344.2019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
121 Saleh MS, Siddiqui MJ, Mediani A, Ahmed QU, Mat So'ad SZ, Saidi-besbes S, Elnaem MH, Othman HA, Ismail NH. Modulation of metabolic alterations of obese diabetic rats upon treatment with Salacca zalacca fruits extract using 1H NMR-based metabolomics. Food Research International 2020;137:109547. [DOI: 10.1016/j.foodres.2020.109547] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
122 Dai X, Hou H, Zhang W, Liu T, Li Y, Wang S, Wang B, Cao H. Microbial Metabolites: Critical Regulators in NAFLD.Front Microbiol. 2020;11:567654. [PMID: 33117316 DOI: 10.3389/fmicb.2020.567654] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
123 Gil-Gómez A, Brescia P, Rescigno M, Romero-Gómez M. Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers. Semin Liver Dis 2021;41:191-205. [PMID: 34107545 DOI: 10.1055/s-0041-1723752] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Barrea L, Annunziata G, Muscogiuri G, Di Somma C, Laudisio D, Maisto M, de Alteriis G, Tenore GC, Colao A, Savastano S. Trimethylamine-N-oxide (TMAO) as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome. Nutrients. 2018;10. [PMID: 30551613 DOI: 10.3390/nu10121971] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 18.5] [Reference Citation Analysis]
125 Brown JM, Hazen SL. Targeting of microbe-derived metabolites to improve human health: The next frontier for drug discovery. J Biol Chem 2017;292:8560-8. [PMID: 28389555 DOI: 10.1074/jbc.R116.765388] [Cited by in Crossref: 52] [Cited by in F6Publishing: 33] [Article Influence: 10.4] [Reference Citation Analysis]
126 Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol 2016;311:G1018-36. [PMID: 27686615 DOI: 10.1152/ajpgi.00245.2016] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 8.7] [Reference Citation Analysis]
127 Shi Q, Dai L, Zhao Q, Zhang X. A review on the effect of gut microbiota on metabolic diseases. Arch Microbiol 2022;204:192. [PMID: 35195774 DOI: 10.1007/s00203-022-02802-3] [Reference Citation Analysis]
128 Zhong QW, Wu YY, Xiong F, Liu M, Liu YP, Wang C, Chen YM. Higher flavonoid intake is associated with a lower progression risk of non-alcoholic fatty liver disease in adults: a prospective study. Br J Nutr 2021;125:460-70. [PMID: 32713378 DOI: 10.1017/S0007114520002846] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
129 Vallianou N, Christodoulatos GS, Karampela I, Tsilingiris D, Magkos F, Stratigou T, Kounatidis D, Dalamaga M. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Biomolecules 2022;12:56. [DOI: 10.3390/biom12010056] [Reference Citation Analysis]
130 Kummen M, Vesterhus M, Trøseid M, Moum B, Svardal A, Boberg KM, Aukrust P, Karlsen TH, Berge RK, Hov JR. Elevated trimethylamine-N-oxide (TMAO) is associated with poor prognosis in primary sclerosing cholangitis patients with normal liver function. United European Gastroenterol J 2017;5:532-41. [PMID: 28588885 DOI: 10.1177/2050640616663453] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
131 Mafra D, Esgalhado M, Borges NA, Cardozo LFMF, Stockler-pinto MB, Craven H, Buchanan SJ, Lindholm B, Stenvinkel P, Shiels PG. Methyl Donor Nutrients in Chronic Kidney Disease: Impact on the Epigenetic Landscape. The Journal of Nutrition 2019;149:372-80. [DOI: 10.1093/jn/nxy289] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
132 Dongiovanni P, Paolini E, Corsini A, Sirtori CR, Ruscica M. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. Eur J Clin Invest 2021;51:e13519. [PMID: 33583033 DOI: 10.1111/eci.13519] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
133 Sharpton SR, Yong GJM, Terrault NA, Lynch SV. Gut Microbial Metabolism and Nonalcoholic Fatty Liver Disease. Hepatol Commun 2019;3:29-43. [PMID: 30619992 DOI: 10.1002/hep4.1284] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
134 Zhang L, She ZG, Li H, Zhang XJ. Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis. Clin Sci (Lond) 2020;134:1775-99. [PMID: 32677680 DOI: 10.1042/CS20200446] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
135 Tan X, Liu Y, Long J, Chen S, Liao G, Wu S, Li C, Wang L, Ling W, Zhu H. Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease. Mol Nutr Food Res. 2019;63:e1900257. [PMID: 31095863 DOI: 10.1002/mnfr.201900257] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 12.0] [Reference Citation Analysis]
136 Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2020;69:1691-705. [PMID: 32321858 DOI: 10.1136/gutjnl-2020-320622] [Cited by in Crossref: 130] [Cited by in F6Publishing: 96] [Article Influence: 65.0] [Reference Citation Analysis]
137 Kao D, Ismond KP, Tso V, Millan B, Hotte N, Fedorak RN. Urine-based metabolomic analysis of patients with Clostridium difficile infection: a pilot study. Metabolomics 2016;12. [DOI: 10.1007/s11306-016-1080-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB, Sirlin CB, Schnabl B, Brinkac L, Schork N, Chen CH, Brenner DA, Biggs W, Yooseph S, Venter JC, Nelson KE. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017;25:1054-1062.e5. [PMID: 28467925 DOI: 10.1016/j.cmet.2017.04.001] [Cited by in Crossref: 349] [Cited by in F6Publishing: 334] [Article Influence: 87.3] [Reference Citation Analysis]
139 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15:397-411. [PMID: 29748586 DOI: 10.1038/s41575-018-0011-z] [Cited by in Crossref: 483] [Cited by in F6Publishing: 422] [Article Influence: 161.0] [Reference Citation Analysis]
140 Li Y, Jiang W, Feng Y, Wu L, Jia Y, Zhao R. Betaine Alleviates High-Fat Diet-Induced Disruptionof Hepatic Lipid and Iron Homeostasis in Mice. Int J Mol Sci 2022;23:6263. [PMID: 35682942 DOI: 10.3390/ijms23116263] [Reference Citation Analysis]
141 Oh HYP, Visvalingam V, Wahli W. The PPAR-microbiota-metabolic organ trilogy to fine-tune physiology. FASEB J 2019;33:9706-30. [PMID: 31237779 DOI: 10.1096/fj.201802681RR] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 5.7] [Reference Citation Analysis]
142 Caussy C, Hsu C, Lo MT, Liu A, Bettencourt R, Ajmera VH, Bassirian S, Hooker J, Sy E, Richards L, Schork N, Schnabl B, Brenner DA, Sirlin CB, Chen CH, Loomba R; Genetics of NAFLD in Twins Consortium. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology 2018;68:918-32. [PMID: 29572891 DOI: 10.1002/hep.29892] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 20.8] [Reference Citation Analysis]